CRL250516C95000
- 15.00
- 0.000.00%
Charles River Newsroom
Trump wants to impose tariffs on Pharmaceuticals: Pharmaceutical companies are busy stockpiling, and the import volume in the USA surged in March.
① The volume of Pharmaceutical imports in the USA surged in March, as pharmaceutical companies stockpiled products in anticipation of potential tariffs; ② A report released by the US Department of Commerce on Tuesday showed that the total value of Pharmaceutical imports in March exceeded 50 billion USD, equivalent to 20% of the total Pharmaceutical imports for the entire year of 2024.
Here Are the Major Earnings Before the Open Tomorrow
Charles River Laboratories Q1 2025 Earnings Preview
Charles River Laboratories (CRL) To Report Earnings Tomorrow: Here Is What To Expect
10 Health Care Stocks Whale Activity In Today's Session
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Could Be 41% Below Their Intrinsic Value Estimate
Wall Street Roars Back From April Tariff Sell-Off: Which Sectors Are Still Underwater?
Earnings Preview: CRL to Report Financial Results Pre-market on May 07
Charles River Associates Backs FY25 Revenue View $715M-$735M, Consensus $718.35M
Press Release: Charles River Associates (CRA) Declares Quarterly Cash Dividend of $0.49 Per Common Share
Press Release: Charles River Associates (CRA) Reports Financial Results for the First Quarter of 2025
Earnings Flash (CRAI) CHARLES RIVER ASSOCIATES Reports Q1 Adjusted EPS $2.22, Vs. FactSet Est of $1.95
Express News | Charles River Associates (CRA) Reports Financial Results for the First Quarter of 2025
Charles River Associates Declares Dividend of 49c >CRAI
Charles River Announces Inaugural Advanced Therapy Incubator Program Cohort
Goldman Sachs: The Q1 performance of U.S. pharmaceutical stocks is reassuring, and the Industry sentiment is slightly becoming more positive.
Goldman Sachs stated that amid cautious sentiment from investors towards the USA pharmaceutical sector before the Earnings Reports season, the performance of USA pharmaceutical companies that have reported results so far for the first quarter has not been worse than expected, and in some cases, it has even exceeded expectations.
Notable Healthcare Headlines for the Week: Merck, Roche and Bausch Health in Focus
The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
Vanda Claims FDA 'Unlawfully' Delays Hearing Request on Tradipitant Decision
9 Health Care Stocks With Whale Alerts In Today's Session